#USA #Stratford #KUBTEC #TomoRad #X-ray Irradiator

KUBTEC® Scientific Unveils the XCELL® TomoRad™ X-ray Irradiator

In a significant advancement for preclinical research, KUBTEC® Scientific, a leader in X-ray imaging and irradiation technology, has launched the XCELL® TomoRad™ system. This innovative device creates a new category for image-guided radiotherapy (IGRT) with the promise of improving research outcomes in various fields, particularly cancer studies.

Revolutionary Imaging Techniques

The XCELL® TomoRad™ system introduces a pioneering imaging technique known as tomosynthesis. This 3D imaging method captures multiple X-ray images from different angles to reconstruct a precise three-dimensional representation of a targeted area. Compared to traditional micro-computed tomography (microCT), this technique significantly reduces radiation exposure to samples, accelerates image acquisition and reconstruction processes, and lowers overall costs.

Historically, existing IGRT systems have been prohibitively expensive and complex, creating barriers for many researchers. This challenge inspired KUBTEC's scientific team to develop the TomoRad system, intending to broaden the accessibility of IGRT technologies across numerous laboratories.

Innovations Paving the Way

One of the standout features of the XCELL® TomoRad™ is its rapid dose delivery method, known as Mag Mode™ (patent pending). This unique system automatically positions the sample closer to the X-ray tube, optimizing dosage within the shortest time frame possible. For busy research laboratories, Mag Mode not only streamlines treatment durations but also helps minimize the time animals spend under anesthesia, thus reducing stress for both the subjects and the researchers.

Vikram Butani, CEO of KUBTEC Scientific, discussed the vision behind the XCELL® TomoRad™. He emphasized the need for more efficient and simpler research workflows and acknowledged that the previous IGRT systems often presented a challenging balance between precision and operational efficiency. Butani stated, "The barriers to image-guided radiotherapy for researchers have been significant due to slow imaging and treatment processes, compounded by the high costs and complexities of available solutions. By addressing these issues, we hope to enhance research capabilities, leading to better clinical care."

The XCELL® TomoRad™ is expected to further KUBTEC's commitment to developing preclinical technologies that empower researchers to innovate and translate their findings into improved healthcare solutions for patients.

A Commitment to Innovation

Beyond its new irradiator, KUBTEC® Scientific has dedicated over 20 years to advancing transformative technologies for preclinical applications. Their critical focus on patent-protected innovations ensures researchers have access to exceptional tools for tackling the most demanding questions in disease investigation.

As the landscape of medical research evolves, devices like the XCELL® TomoRad™ are pivotal in enhancing the quality and speed of studies. KUBTEC's advancements provide not only groundbreaking opportunities for laboratories but also a hopeful outlook towards future medical advancements, particularly in the treatment of cancer.

To learn more about the XCELL® TomoRad™ image-guided radiotherapy system, visit KUBTEC Scientific.